Clinical pharmacology of antiplatelet drugs.
Georg GelbeneggerBernd JilmaPublished in: Expert review of clinical pharmacology (2022)
inhibitors, all of which lead to an attenuated antiplatelet effect. Platelet function and genetic testing and the use of scores (ARC-HBR, PRECISE-DAPT, ESC ischemic risk definition) may contribute to a more tailored antiplatelet therapy. High on-treatment platelet reactivity presents a key problem in the acute management of ST-elevation myocardial infarction (STEMI). A treatment strategy involving early initiation of an intravenous antiplatelet agent may be able to bridge the gap of insufficient platelet inhibition in high ischemic risk patients with STEMI.
Keyphrases
- percutaneous coronary intervention
- st elevation myocardial infarction
- antiplatelet therapy
- st segment elevation myocardial infarction
- acute coronary syndrome
- coronary artery disease
- liver failure
- intensive care unit
- atrial fibrillation
- ischemia reperfusion injury
- low dose
- hepatitis b virus
- drug induced
- cerebral ischemia
- blood brain barrier
- smoking cessation